Ironwood Pharma (IRWD) AI Stock Analysis

• Market Cap: $509.18M
• Dividend Yield: N/A
• Average Volume (3M): 1.44M
• Price to Earnings (P/E): 20.9
• Beta (1Y): 0.71
• Revenue Growth: -10.42%
• EPS Growth: N/A
• Country: US
• Employees: 253
• Sector: N/A
• Sector Strength: N/A
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.23
• Shares Outstanding: 162,678,650
• 10 Day Avg. Volume: 1,975,296
• 30 Day Avg. Volume: 1,437,330
• PEG Ratio: -8.00
• Price to Book (P/B): -2.34
• Price to Sales (P/S): 2.01
• P/FCF Ratio: 6.82
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $4.00 ▲(95.12% Upside)

Ironwood Pharma's overall stock score is primarily influenced by its financial performance challenges, including negative profitability and high leverage. The technical analysis shows strong bullish momentum, but the overbought conditions could pose a risk. Valuation is moderate, with a P/E ratio of 25, but the lack of a dividend yield limits immediate income potential. Addressing financial stability issues is crucial for long-term growth.

Ironwood Pharma Business Overview & Revenue Model

Company Description

Ironwood Pharmaceuticals, Inc. is a biotechnology company focused on the development and commercialization of innovative therapies for gastrointestinal diseases. The company primarily operates in the biopharmaceutical sector, with a strong emphasis on enhancing the quality of life for patients suffering from conditions such as irritable bowel syndrome and chronic idiopathic constipation. Ironwood's core products include Linzess (linaclotide), a prescription medication that promotes intestinal motility and alleviates abdominal discomfort associated with these conditions.

How the Company Makes Money

Ironwood Pharmaceuticals generates revenue primarily through the sales of its flagship product, Linzess, which is marketed in collaboration with AbbVie. The company earns royalties from its partner on sales of Linzess, in addition to receiving milestone payments tied to sales performance. Other revenue streams may include licensing agreements and collaborations that provide upfront payments and development milestones. The company's focus on expanding its product pipeline and potential new indications for existing therapies also contributes to its earnings potential.

Ironwood Pharma Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Ironwood Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRWD, the sentiment is Positive. The current price of 2.05 is below the 20-day moving average (MA) of 3.50, below the 50-day MA of 2.68, and above the 200-day MA of 1.43, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 50.14 is Neutral, neither overbought nor oversold. The STOCH value of 9.55 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRWD.

Ironwood Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
COLL	71 Outperform	$1.55B	30.40	22.96%	―	26.34%	-32.79%
DVAX	70 Outperform	$1.28B	―	-7.14%	―	26.73%	-310.39%
PCRX	69 Neutral	$1.13B	58.33	2.90%	―	3.14%	―
ANIP	64 Neutral	$1.86B	49.50	7.83%	―	48.87%	―
IRWD	54 Neutral	$509.18M	20.92	―	―	-10.42%	―
EVO	46 Neutral	$1.08B	-6.02	-17.46%	―	-1.19%	5.06%

Ironwood Pharma Corporate Events

Ironwood Pharma’s LINZESS® Price Set by HHS

On November 25, 2025, the U.S. Department of Health and Human Services announced the ‘Maximum Fair Price’ for LINZESS® (linaclotide) as part of the Inflation Reduction Act of 2022. The new Medicare net price, effective January 1, 2027, will be $136 for a 30-day supply, aligning with Ironwood Pharmaceuticals’ expectations.

Ironwood Pharma Board Member Resigns for New Role

On October 7, 2025, Andrew Dreyfus announced his resignation from the Board of Directors of Ironwood Pharmaceuticals, Inc., effective November 1, 2025. His departure is due to his new role as President and CEO of the National Institute for Health Care Management Foundation and is not related to any disagreements with Ironwood Pharmaceuticals. The company expressed gratitude for his contributions during his tenure.